{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:12:24Z","timestamp":1790190744433,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.trsl.2014.10.010","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T06:20:41Z","timestamp":1413786041000},"page":"306-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome"],"prefix":"10.1016","volume":"165","author":[{"given":"Edwin K.S.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2014.10.010_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri1994","article-title":"T-cell regulation: with complements from innate immunity","volume":"7","author":"Kemper","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0065-2776(07)96004-6","volume":"96","author":"Richards","year":"2007","journal-title":"Adv Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.blre.2007.10.002","article-title":"Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria","volume":"22","author":"Brodsky","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.trsl.2014.10.010_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib7","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.4049\/jimmunol.0804031","article-title":"The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome","volume":"182","author":"Ferreira","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib8","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1681\/ASN.2013070732","article-title":"Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN","volume":"25","author":"Wong","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib9","first-page":"5883","article-title":"Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration","volume":"123","author":"Yu","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trsl.2014.10.010_bib10","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/ng.2741","article-title":"Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration","volume":"45","author":"Seddon","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2014.10.010_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molimm.2006.07.004","article-title":"Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome","volume":"44","author":"Richards","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2007.01.046","article-title":"The pathophysiology of paroxysmal nocturnal hemoglobinuria","volume":"35","author":"Parker","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.V74.1.437.437","article-title":"The Inab phenotype: characterization of the membrane protein and complement regulatory defect","volume":"74","author":"Telen","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2012-07-441857","article-title":"CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy","volume":"121","author":"Nevo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.trsl.2014.10.010_bib17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib18","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.173.6.1483","article-title":"The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region","volume":"173","author":"Canfield","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.178.2.661","article-title":"Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation","volume":"178","author":"Tao","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib20","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1073\/pnas.92.19.8955","article-title":"Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2014.10.010_bib21","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","article-title":"Amelioration of lupus-like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5","volume":"93","author":"Wang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2014.10.010_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1191\/0961203303lu1021oa","article-title":"Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus","volume":"13","author":"Rother","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2014.10.010_bib23","first-page":"S77","article-title":"A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis","volume":"42","author":"Jain","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2014.10.010_bib24","first-page":"S274","article-title":"Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis","volume":"44","author":"Tesser","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2014.10.010_bib25","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","article-title":"Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Hill","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.trsl.2014.10.010_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0029-1196307","article-title":"Paroxysmale haemoglobinurie","volume":"8","author":"Strubing","year":"1882","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.trsl.2014.10.010_bib28","first-page":"3","article-title":"Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease","volume":"5","author":"Dacie","year":"1972","journal-title":"Ser Haematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib29","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1172\/JCI101081","article-title":"Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunological aspects of the hemolytic mechanism with special reference to serum complement","volume":"18","author":"Ham","year":"1939","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2014.10.010_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1126\/science.120.3112.279","article-title":"The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena","volume":"120","author":"Pillemer","year":"1954","journal-title":"Science"},{"key":"10.1016\/j.trsl.2014.10.010_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0065-2776(08)60584-2","article-title":"Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria","volume":"60","author":"Kinoshita","year":"1995","journal-title":"Adv Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib33","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1073\/pnas.96.9.5209","article-title":"Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals","volume":"96","author":"Araten","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2014.10.010_bib34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1365-2141.2001.03127.x","article-title":"Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia","volume":"115","author":"Mukhina","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib35","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood-2006-05-025148","article-title":"Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH)","volume":"108","author":"Inoue","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib36","doi-asserted-by":"crossref","first-page":"8756","DOI":"10.1073\/pnas.94.16.8756","article-title":"Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria","volume":"94","author":"Brodsky","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2014.10.010_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3324\/haematol.2008.001297","article-title":"Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure","volume":"94","author":"Young","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2014.10.010_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12013-012-9435-1","article-title":"Potential link between MHC-self-peptide presentation and hematopoiesis; the analysis of HLA-DR expression in CD34-positive cells and self-peptide presentation repertoires of MHC molecules associated with paroxysmal nocturnal hemoglobinuria","volume":"65","author":"Nowak","year":"2013","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.trsl.2014.10.010_bib39","first-page":"219","article-title":"Paroxysmal nocturnal hemoglobinuria\u2014present status and future prospects","volume":"132","author":"Rosse","year":"1980","journal-title":"West J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib40","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1172\/JCI112773","article-title":"Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in\u00a0vivo","volume":"79","author":"Devine","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2014.10.010_bib42","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V82.4.1192.1192","article-title":"Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria","volume":"82","author":"Wiedmer","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib43","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.293.13.1653","article-title":"The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease","volume":"293","author":"Rother","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2014.10.010_bib44","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2141.1995.tb05371.x","article-title":"Activated platelets in paroxysmal nocturnal haemoglobinuria","volume":"91","author":"Gralnick","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib45","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood.V79.6.1447.1447","article-title":"The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria","volume":"79","author":"Ploug","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib46","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1538-7836.2006.01873.x","article-title":"A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression","volume":"4","author":"Maroney","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trsl.2014.10.010_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V57.1.83.83","article-title":"The kidneys in paroxysmal nocturnal hemoglobinuria","volume":"57","author":"Clark","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1523-1755.2001.00471.x","article-title":"Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1","volume":"59","author":"Nath","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.10.010_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/HJH.0b013e3282f1a93e","article-title":"Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans","volume":"26","author":"Schlaich","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.trsl.2014.10.010_bib50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/1097-0320(20000815)42:4<223::AID-CYTO2>3.0.CO;2-D","article-title":"Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria","volume":"42","author":"Richards","year":"2000","journal-title":"Cytometry"},{"key":"10.1016\/j.trsl.2014.10.010_bib51","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1160\/TH04-06-0391","article-title":"High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria","volume":"93","author":"Araten","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.trsl.2014.10.010_bib53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.md.0000126763.68170.46","article-title":"Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan","volume":"83","author":"Nishimura","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trsl.2014.10.010_bib54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","article-title":"Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria","volume":"85","author":"Hillmen","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib55","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib56","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib57","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib58","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","article-title":"Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial","volume":"93","author":"Kanakura","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-013-1404-y","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial","volume":"98","author":"Kanakura","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12021","article-title":"Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria","volume":"90","author":"DeZern","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib62","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/pbc.25068","article-title":"Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria","volume":"61","author":"Reiss","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.trsl.2014.10.010_bib63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.medcli.2010.09.035","article-title":"Paroxysmal nocturnal hemoglobinuria therapy with eculizumab: Spanish experience","volume":"137","author":"Lopez Rubio","year":"2011","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.trsl.2014.10.010_bib64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib65","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2010.08096.x","article-title":"Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria","volume":"149","author":"Hill","year":"2010","journal-title":"Br J Haematol"},{"issue":"12 suppl","key":"10.1016\/j.trsl.2014.10.010_bib66","first-page":"ECR40","article-title":"Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria","volume":"90","author":"Hill","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2014.10.010_bib67","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2014.10.010_bib69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2013.090001","article-title":"Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Rondelli","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2014.10.010_bib70","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2009-09-244285","article-title":"A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement","volume":"115","author":"Lindorfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib71","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib72","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib73","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2013-11-536573","article-title":"Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"123","author":"Risitano","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib74","doi-asserted-by":"crossref","first-page":"e87316","DOI":"10.1371\/journal.pone.0087316","article-title":"Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2014.10.010_bib75","unstructured":"England N. 2013\/14 NHS Standard contract for paroxysmal nocturnal haemoglobinuria service (adults and adolescents). 2013 [cited 2014 Oct 15th]. Available at: http:\/\/www.england.nhs.uk\/wp-content\/uploads\/2013\/06\/b05-parox-haem-serv.pdf."},{"key":"10.1016\/j.trsl.2014.10.010_bib76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.med.59.060106.185110","article-title":"Complement regulatory genes and hemolytic uremic syndromes","volume":"59","author":"Kavanagh","year":"2008","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib77","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.ki.5001581","article-title":"A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders","volume":"70","author":"Besbas","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.10.010_bib78","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.trsl.2014.10.010_bib79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2249.2007.03553.x","article-title":"Translational mini-review series on complement factor H: structural and functional correlations for factor H","volume":"151","author":"Schmidt","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib80","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.10.010_bib81","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2014.10.010_bib83","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"Jozsi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib84","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","author":"Blanc","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib85","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2215\/CJN.05750611","article-title":"Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?","volume":"7","author":"Kavanagh","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib86","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1084\/jem.20070301","article-title":"Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains","volume":"204","author":"Pickering","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib87","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/jmg.2005.030783","article-title":"The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts","volume":"42","author":"Fremeaux-Bacchi","year":"2005","journal-title":"J Med Genet"},{"key":"10.1016\/j.trsl.2014.10.010_bib88","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2014.10.010_bib89","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib90","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib91","doi-asserted-by":"crossref","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","article-title":"Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases","volume":"127","author":"Hosler","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib92","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib93","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2014.10.010_bib94","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical hemolytic uremic syndrome depends on complement C5","volume":"22","author":"de Jorge","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib95","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib96","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"Nurnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib97","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molimm.2013.05.224","article-title":"Complement therapy in atypical haemolytic uraemic syndrome (aHUS)","volume":"56","author":"Wong","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trsl.2014.10.010_bib98","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib99","unstructured":"Alexion. SPC soliris. 2014 [cited 2014 Oct 15th]. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/19966."},{"key":"10.1016\/j.trsl.2014.10.010_bib100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2014.10.010_bib101","first-page":"326","article-title":"Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis","volume":"82","author":"Povey","year":"2013","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib102","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2014.10.010_bib103","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","author":"Ozaltin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib104","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2014.10.010_bib105","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib106","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/ndt\/gfq319","article-title":"Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation","volume":"25","author":"Loirat","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2014.10.010_bib107","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08099.x","article-title":"The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab","volume":"149","author":"Kelly","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2014.10.010_bib108","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.leukres.2009.10.025","article-title":"Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab","volume":"34","author":"Danilov","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.trsl.2014.10.010_bib109","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"2 Pt 2","key":"10.1016\/j.trsl.2014.10.010_bib110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","article-title":"Eculizumab for atypical hemolytic uremic syndrome in pregnancy","volume":"122","author":"Ardissino","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.trsl.2014.10.010_bib111","doi-asserted-by":"crossref","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.trsl.2014.10.010_bib112","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.10.010_bib113","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.10.010_bib114","unstructured":"British national formulary: London: British Medical Association\/Pharmaceutical Society of Great Britain."}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524414003831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524414003831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T04:22:19Z","timestamp":1650428539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524414003831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1931524414003831"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2014.10.010","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2014.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}